Liver international : official journal of the International Association for the Study of the Liver · 2025
Physical Activity by Accelerometer Inversely Associated With Liver Fibrosis; Cross-Sectional Analysis of a Longitudinal Cohort.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Haff Madeleine G, Murabito Joanne M, Vasan Ramachandran S, Spartano Nicole L, Liu Ching-Ti, Zhang Xiaoyu, Benjamin Emelia J, Lewis Gregory D, Long Michelle T
Аннотация
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) can progress from hepatic steatosis to liver fibrosis and cirrhosis. Advanced fibrosis is associated with increased mortality. Physical activity (PA) is important in treatment and prevention, but its association with hepatic fibrosis is not well characterised.
METHODS: We examined the cross-sectional association between accelerometer-measured PA and fibrosis measured by vibration-controlled transient elastography. Primary covariates included age, sex, cohort, smoking status, alcohol use and accelerometer wear time. Secondary covariates included body mass index (BMI) and hepatic steatosis. The primary dependent variable was continuous liver stiffness measurement (LSM), and the secondary dependent variable was dichotomous liver fibrosis (LSM > 8.2 kPa). We performed sex-specific, age-adjusted Pearson correlation coefficients, as well as multivariable-adjusted linear and logistic regression models.
RESULTS: In our study sample (n = 2201, 54.1% women, average age 54 years old, average BMI 27.1 kg/m2) the prevalence of fibrosis was 7.7%. Each additional 30 min spent in moderate-vigorous PA (MVPA)/day was associated with a lower odds of fibrosis (odds ratio 0.57; 95% confidence interval 0.41, 0.79) even after adjusting for BMI (0.72; 0.53, 0.99) or steatosis (0.70; 0.51, 0.96). Those who achieved at least 150 min/week of MVPA had the lowest odds of hepatic fibrosis (0.51; 0.35, 0.75) even when adjusted for BMI (0.64; 0.44, 0.95) or steatosis (0.61; 0.42, 0.90).
CONCLUSIONS: In our community-based cross-sectional cohort study, there was an inverse association between time spent in MVPA and liver fibrosis, even when adjusting for BMI or steatosis. Additional interventional studies are needed to determine if MVPA can reverse liver fibrosis.
METHODS: We examined the cross-sectional association between accelerometer-measured PA and fibrosis measured by vibration-controlled transient elastography. Primary covariates included age, sex, cohort, smoking status, alcohol use and accelerometer wear time. Secondary covariates included body mass index (BMI) and hepatic steatosis. The primary dependent variable was continuous liver stiffness measurement (LSM), and the secondary dependent variable was dichotomous liver fibrosis (LSM > 8.2 kPa). We performed sex-specific, age-adjusted Pearson correlation coefficients, as well as multivariable-adjusted linear and logistic regression models.
RESULTS: In our study sample (n = 2201, 54.1% women, average age 54 years old, average BMI 27.1 kg/m2) the prevalence of fibrosis was 7.7%. Each additional 30 min spent in moderate-vigorous PA (MVPA)/day was associated with a lower odds of fibrosis (odds ratio 0.57; 95% confidence interval 0.41, 0.79) even after adjusting for BMI (0.72; 0.53, 0.99) or steatosis (0.70; 0.51, 0.96). Those who achieved at least 150 min/week of MVPA had the lowest odds of hepatic fibrosis (0.51; 0.35, 0.75) even when adjusted for BMI (0.64; 0.44, 0.95) or steatosis (0.61; 0.42, 0.90).
CONCLUSIONS: In our community-based cross-sectional cohort study, there was an inverse association between time spent in MVPA and liver fibrosis, even when adjusting for BMI or steatosis. Additional interventional studies are needed to determine if MVPA can reverse liver fibrosis.